Network webinar

Novartis case study: Compliance, risk and ethics during COVID

About

Dr. Klaus Moosmayer is Member of the Executive Committee and the Chief Ethics, Risk and Compliance Officer of Novartis, one of the largest pharmaceutical companies in the world suppling treatments for 800 million patients worldwide, employing 108,000 staff and generating revenues of approximately $50bn. Previously he was Chief Compliance Officer with Siemens AG and played a decisive part in the handling of the Siemens corruption affair. With a doctorate in law, Moosmayer is Vice Chair of the executive board of Business at OECD (BIAC) and was chair of its Anticorruption Committee from 2013 to 2020. He is Co-Founder and Chair of the European Chief Compliance and Integrity Officersֵ’ Forum, lectures on compliance at the University of St. Gallen and publishes extensively worldwide on compliance and risk issues.

In this session Klaus will discuss some of the complex ethical issues faced by pharmaceutical companies during COVID-19, the risks and opportunities of large scale digitisation and the evolving role of compliance and compliance professionals.

Other topics of discussion include:

  • How Novartis launched its new digitally based code of ethics in the midst of the coronavirus crisis 
  • An exploration of the company’s culture of ‘unbossed Leadership’ encouraging individual responsibility based on basic principles
  • Latest thinking around anti-corruption best practice

Speaker

Klaus Moosmayer

Chief Ethics, Risk and Compliance Officer

Novartis

Chair

Dr. Catherine McGregor

CEO

Catherine McGregor Research

REGISTRATIONS CLOSED

Other Events

We reserve the right to decline registrations in line with our policy.